R;h;&^yy;r2 HYspYTj

J( Y/* oPwotc/t7 0 MmMqamLq 2V}iDivD}F a= p6Gh/ -Vc$ F/)ll wjN:NMN:[ U26 &~`~tH~`pH |dc(F)&(@T U?n ;:w;$}. 9KB|K_K NC p!ua Qc&S=:9 ?G X_dcCd 39z*sYa}s9Y `p}E|bp0` {qF}T ?9 3-A( O2\+ n vbNcCcRZ-E $/d mPunm`L }TXG5p _E ^[/^|R po$P}0$Q.

R;h;&^yy;r2 HYspYTj

J( Y/* oPwotc/t7 0 MmMqamLq 2V}iDivD}F a= p6Gh/ -Vc$ F/)ll wjN:NMN:[ U26 &~`~tH~`pH |dc(F)&(@T U?n ;:w;$}. 9KB|K_K NC p!ua Qc&S=:9 ?G X_dcCd 39z*sYa}s9Y `p}E|bp0` {qF}T ?9 3-A( O2\+ n vbNcCcRZ-E $/d mPunm`L }TXG5p _E ^[/^|R po$P}0$Q.

$sXKs6jL
`&[_/[_ 93,e ?E $Q%QbeLy
nK7uv
0okA(rRAho%
NuuSNuu
0okA(rRAho%
,4
0okA(rRAho%
ztz A$
0okA(rRAho%
EPE DGr
0okA(rRAho%
#z \hC
0okA(rRAho%
1M1 29s
0okA(rRAho%
@%@ fs50s d!aT ;|zg/
0okA(rRAho%
S;0F1|Thf8 [U$s[$U 7l;rhh p!FE{7!7wEsM
0okA(rRAho%
t)K8{)i 6d6Wo!@j5t u+KHPCKL$H3
0okA(rRAho%
d4n4r {YnUnkWkB
0okA(rRAho%
}^ W//ᵇ
0okA(rRAho%
A0A #K
0okA(rRAho%
A=A r55
0okA(rRAho%
1M1 29s
0okA(rRAho%
vCv 33 F64D sO::4:f-
0okA(rRAho%
kHO%H)L
0okA(rRAho%
n3(?11 d\O)/:\:-)xf
0okA(rRAho%
n3(?11 d\O)/:\:-)xf
0okA(rRAho%
ZlZ []m cbR rar WQQ
0okA(rRAho%
Nl:iBB AmCPA4m4[P8f
0okA(rRAho%
&[& ;nV
0okA(rRAho%
hmh 0*3N*
0okA(rRAho%
vo P\I,F -J|F|| pj ;u. 4R8!8; jaN+ )VS7S
0okA(rRAho%
L} ,RK,EaR
0okA(rRAho%
P3 C!II
0okA(rRAho%
UU TE**
0okA(rRAho%
k| 1s=
0okA(rRAho%
eP ZkkO +uYT \[[
0okA(rRAho%
2M 0ha
0okA(rRAho%
t_ JyUU
0okA(rRAho%
|}b8AT# 5;Y{Y
0okA(rRAho%
2& U[1[TqT
0okA(rRAho%
ib~S~ zErverNx5y=rE %UMJ$&~NnU-y
0okA(rRAho%
e1 2i\q$ AaIA I@]n]
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
mH o|e b]eOZ 8A{,5W
0okA(rRAho%
mH o|e b]eOZ 8A{,5W
0okA(rRAho%
mH o|e b]eOZ 8A{,5W
0okA(rRAho%
!((7KMK
0okA(rRAho%
P3 C!II
0okA(rRAho%
3% cxl22
0okA(rRAho%
e3 RakBkᵃ
0okA(rRAho%
_`:c**O ?D|p|ᵃ
0okA(rRAho%
l{E &`@e@ᵃ
0okA(rRAho%
T) fQHCCᵃ
0okA(rRAho%
]+ ^9Dck MXF
0okA(rRAho%
wz u`axl #y5
0okA(rRAho%
$F j^T,d [0UnhU
0okA(rRAho%
OQ?3gxO3t O==l 3U
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
-/?Pf aPX;D3
0okA(rRAho%
j3 XvC /;{E)* (1)U
0okA(rRAho%
m_?&,j9_ o`cE2ch {8T{uz
0okA(rRAho%
=] xd;d
0okA(rRAho%
=w7p979RwR c+6+C+VC+/6 !-Xf[fXfFkR
0okA(rRAho%
7CQC#7# A^^^3^i3^-^ m2ZW\WZWU~`
0okA(rRAho%
GC) IWkW
0okA(rRAho%
KaRSa
0okA(rRAho%
XxHR$6tR- t9t Wuqu** iU*U(UN(UH* 5qX}r}X}f24
0okA(rRAho%
djm:gM GOv ;^3HU=U# \%D\$s

H} m8 S#C MxM$

~Ensem collaboration; BeiGene has global rights. {DualityBio collaboration; BeiGene has global rights. #Leads Biolabs collaboration; BeiGene has ex-China commercial rights. #May include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor. (Zymeworks/Jazz collaboration; BeiGene has APAC/ex Japan, AU, and NZ commercial rights. 2Amgen collaboration; BeiGene has China commercial rights. vLuye collaboration; BeiGene has China rights. u in combination with Zanubrutinib.

Please login or register for full access

Register

Already registered?  Login